Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Temporarily Pauses Two AZD9291 Combo Trials on Lung Disease Incidences
- Hertz (HTZ) Shares Ramp to Session Highs Following Lyft News
- Celgene (CELG) Plans Otezla Presentations at 24th EADV
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!